Literature DB >> 6573535

In vivo selection of androgen-insensitive cells in R3327-G rat prostate tumors: diethylstilbestrol diphosphate treatment versus orchiectomy.

A Pollack, N L Block, B J Stover, G L Irvin, M P Fuentes, A J Claflin, T I Malinin.   

Abstract

Tumors grown in diethylstilbestrol diphosphate (DES)-treated rats grew significantly more slowly than tumors grown in orchiectomized animals, and tumors grown in orchiectomized animals grew significantly more slowly than tumors grown in controls (intact male rats). When these tumors (phase I) were dispersed and reimplanted into DES-treated, orchiectomized, or control rats in all possible combinations (phase II), a partial selection of androgen-insensitive cells was observed in tumors grown in DES-treated animals. Tumors grown in DES-treated phase I animals responded significantly less to DES treatment or orchiectomy in phase II. In contrast, tumors from phase I orchiectomized animals showed the same responses to orchiectomy in phase II. Since the administration of exogenous testosterone propionate prevented the growth rate inhibitory effects of both DES treatment and orchiectomy, the added effect of DES seemed to be antiandrogenic.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6573535

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  4 in total

1.  A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02.

Authors:  Alan Pollack; James J Dignam; Dayssy A Diaz; Qian Wu; Radka Stoyanova; Kyounghwa Bae; Adam P Dicker; Howard Sandler; Gerald E Hanks; Felix Y Feng
Journal:  Clin Cancer Res       Date:  2014-10-07       Impact factor: 12.531

2.  The tumor-inhibiting effect of diethylstilbestrol and its diphosphate on the Nb-H and Nb-R prostatic carcinomas of the rat.

Authors:  M R Schneider; A Humm; A H Graf
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

3.  Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo.

Authors:  Zhaomei Mu; Paul Hachem; Harvey Hensley; Radka Stoyanova; Hae Won Kwon; Alexandra L Hanlon; Sudhir Agrawal; Alan Pollack
Journal:  Prostate       Date:  2008-05-01       Impact factor: 4.104

4.  Studies on the mammary tumor-inhibiting effects of diethylstilbestrol and its mono- and diphosphate.

Authors:  M R Schneider; E von Angerer; J Prekajac; W P Brade
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.